CleanTech Lithium PLC
FINPROM Findings
6“the maturity date shall be extended to 30 June 2026...if the Company has not entered into a streamlined CEOL process for Laguna Verde by 31 January 2026 the Noteholders will require the Company to engage an M&A investment bank to look at certain strategic options”
Loan notes required restructuring with security over all company assets. Noteholders can force strategic review (potential sale) if CEOL not achieved by Jan 2026, indicating existential funding risk.
“It appears the lithium market is coming off its low...analysts are recognising the current oversupply should turn to deficit soon. The prospect of higher prices can already be seen in strengthening lithium company share prices”
Chairman's statement includes speculative market outlook on lithium prices presented as near-certain, without adequate qualification that these are opinions not facts.
“the second tranche...being a conditional placing of new Ordinary Shares...to raise approximately £3.13 million...each Fundraising Share will carry a warrant entitlement of 1 warrant for every 1 Fundraising Share...Placee Warrants are exercisable at a price of 6 pence”
Placing shares represent ~46% of enlarged share capital, with 1:1 warrant attachment effectively doubling potential dilution. Additionally, loan notes are now convertible at the same issue price.
“The Placing Shares represent approximately 46.2% per cent. of the Company's enlarged ordinary share capital...the Placing Shares will carry a warrant entitlement of one warrant for every Placing Share...exercisable at 6 pence, being at a 20% premium to the Issue Price”
Confirmed 46% dilution from placing alone, with 1:1 warrant attachment creating potential for further massive dilution. Board reduced to two directors as cost-cutting measure.
“Proceeds from the Broker Option (if exercised) (which when aggregated with the proceeds of the Placing, amount to more than £2.4 million) would be applied to repaying Loan Notes”
Broker option proceeds earmarked to repay existing loan notes suggests circular financing, where new equity is used to retire prior debt rather than fund growth.
“Each Warrant grants the holder the right to subscribe for one new Ordinary Share at a price of 11p, being approximately 31% per cent. below the Issue Price, at any time from one year after the date of First Admission until up to 4 years”
Warrants exercisable at 31% below the issue price (11p vs 16p), attached 1:1 to every fundraising share, represent an extraordinary dilution risk. This effectively doubles potential share issuance at a deep discount. [Severity adjusted: discount alone insufficient for high severity without compounding factors.]
RNS Announcements
3Additional Licences, Fundraising & Board Changes
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS …
Results of Placing, Issue of Equity and TVR
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018 ("MAR"). 11 August 2025 CleanTech Lithi…
Proposed interim fundraising and corporate update
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS …
LinkedIn Activity
2CleanTech Lithium opens retail share offer via BookBuild at 5p/share alongside £4.3m placing. Retail offer oversubscribed, raising £250,000.
Proactive Investors shared article on LinkedIn. The placing price of 5p represented significant dilution from earlier raises at 16p. Company had noteholder forced review. No LinkedIn posts found from CleanTech Lithium's own company page or CEO Aldo Boitano specifically promoting the BookBuild retail offer, though the company page shares operational updates regularly.
2026 outlook post highlighting clinical milestones: POLB 001 TOPICAL trial interim data expected summer 2026, Oral GLP-1 PoC topline data expected H1 2026. States company is 'funded through this catalyst-rich period, with a cash runway extending into 2027'.
No direct fundraise announcement found on LinkedIn for Poolbeg. This post emphasises cash runway to 2027. No BookBuild or retail targeting language found in any Poolbeg LinkedIn posts. A separate profile (Michael Fleming) mentioned participating in a Poolbeg share placing with £100k investment, but post not directly accessible. URL: https://www.linkedin.com/posts/poolbeg-pharma_polb-catalystrich-aim-activity-7415289997668360192-LCu-